Institute of Integrative Chinese Medicine, Department of Integrated Chinese Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, PR China; NATCM Key Laboratory of TCM Gan, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, PR China; Hunan Key Laboratory of TCM Gan, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, PR China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, PR China.
Institute of Integrative Chinese Medicine, Department of Integrated Chinese Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, PR China; Department of Neurology of Integrated Chinese Medicine, Xiangya Jiangxi Hospital, Central South University, Nanchang, 330006, PR China; NATCM Key Laboratory of TCM Gan, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, PR China; Hunan Key Laboratory of TCM Gan, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, PR China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, PR China.
J Ethnopharmacol. 2024 Jan 30;319(Pt 1):117123. doi: 10.1016/j.jep.2023.117123. Epub 2023 Sep 4.
Buyang Huanwu Decoction (BYHWD), as a traditional Chinese medical prescription, has been used to treat intracerebral hemorrhage (ICH) for hundreds of years, but the antiapoptotic properties have not yet been studied.
This study aims to elucidate the antiapoptotic mechanism of BYHWD in ICH.
The therapeutic effect of BYHWD on ICH was assessed by modified neurological severity scores (mNSS), foot fault, and histopathological staining. Then, we used a modified comprehensive strategy by integrating transcriptome and network pharmacology to reveal the underlying mechanism. TUNEL assay, qRT-PCR, and western blot were further applied to evaluate the antiapoptotic effect of BYHWD on ICH. Dual-luciferase reporter assay and plasmid transfections were implemented to validate the potential competing endogenous RNAs (ceRNA) mechanism of Sh2b3.
Network pharmacology analysis indicated that the regulation of the apoptotic process was the highest enriched GO term, and that MAP kinase activity, ERK1, and ERK2 cascade were strongly correlated. Transcriptome analysis screened 180 differentially expressed mRNAs, which were highly enriched in the immune system process and negative regulation of programmed cell death. By checking the literature, we found that Sh2b3 was of great importance to apoptosis by modulating MAPK cascades. TUNEL assay validated the anti-apoptotic effect of BYHWD. Moreover, BYHWD was proven to regulate the Sh2b3-mediated ERK1/2 signaling pathway in ICH mice by qRT-PCR and western blot. We further explored the lncRNA-miRNA-mRNA network underlying the therapeutic effect, among which 4933404O12Rik/miR-185-5p is the upstream regulatory mechanism of Sh2b3.
We explored the antiapoptotic mechanism of BYHWD in treating ICH by a novel integrated strategy, which involved the 4933404O12Rik/miR-185-5p/Sh2b3 ceRNAs axis.
补阳还五汤(BYHWD)作为一种传统的中药方剂,已经被用于治疗脑出血(ICH)数百年,但抗细胞凋亡的特性尚未得到研究。
本研究旨在阐明 BYHWD 在 ICH 中的抗细胞凋亡机制。
通过改良神经功能缺损评分(mNSS)、足失误和组织病理学染色评估 BYHWD 对 ICH 的治疗效果。然后,我们使用整合转录组和网络药理学的改良综合策略来揭示潜在的机制。TUNEL 检测、qRT-PCR 和 Western blot 进一步用于评估 BYHWD 对 ICH 的抗细胞凋亡作用。双荧光素酶报告基因检测和质粒转染用于验证 Sh2b3 的潜在竞争性内源 RNA(ceRNA)机制。
网络药理学分析表明,凋亡过程的调节是最富集的 GO 术语,MAP 激酶活性、ERK1 和 ERK2 级联与该术语强烈相关。转录组分析筛选出 180 个差异表达的 mRNA,这些 mRNA 高度富集于免疫系统过程和程序性细胞死亡的负调控。通过查阅文献,我们发现 Sh2b3 通过调节 MAPK 级联对细胞凋亡具有重要意义。TUNEL 检测验证了 BYHWD 的抗凋亡作用。此外,通过 qRT-PCR 和 Western blot,BYHWD 被证明在 ICH 小鼠中调节 Sh2b3 介导的 ERK1/2 信号通路。我们进一步探索了潜在的治疗效果 lncRNA-miRNA-mRNA 网络,其中 4933404O12Rik/miR-185-5p 是 Sh2b3 的上游调节机制。
我们通过一种新的综合策略探索了 BYHWD 治疗 ICH 的抗细胞凋亡机制,该策略涉及 4933404O12Rik/miR-185-5p/Sh2b3 ceRNAs 轴。